Therapeutic area intelligence for Pancreatic Adenocarcinoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Amgen →

Assets

Atebimetinib →

Keytruda →

Recent signals(2)

ClinicalJuly 11, 2026

Atebimetinib + GnP Study for Metastatic Pancreatic Adenocarcinoma Initiated

A clinical trial is underway to assess atebimetinib combined with modified GnP versus standard of care GnP in metastatic pancreatic adenocarcinoma.

ClinicalJune 17, 2026

Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

Amplification of ARHGAP29 and SLC44A3 genes adjacent to F3 is associated with worse overall and disease-free survival in pancreatic adenocarcinoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Pancreatic Adenocarcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.